Selective norepinephrine (NE) reuptake inhibitors improve patients' mood by selectively blocking NE reuptake and increasing the activity of NE in the central nervous system. They have no affinity for serotonin and dopamine reabsorption sites, and almost no affinity for muscarinic, histamine or adrenaline receptors. They are clinically used to treat depression.

This product is a glipizide controlled-release tablet designed according to the special gastrointestinal therapeutic system (GITS). It can maintain the release of active ingredients for about 8 hours, and the release rate will gradually decrease, and the release will be completed about 16 hours after taking the medicine. The elimination half-life of glipizide gradually absorbed into the blood in the intestine is about 2.5 to 4 hours. It can maintain a relatively stable blood drug concentration within 24 hours after taking the medicine. After taking 5 mg orally once, the average blood drug concentration in 24 hours can reach more than 50ng/ml. Taking the medicine once a day can control blood sugar throughout the day.

This product can inhibit the synthesis of prostaglandins and has antipyretic, analgesic and anti-inflammatory effects.

This product has anti-inflammatory, antipyretic and analgesic effects. Its mechanism of action is to reduce the synthesis of prostaglandins by inhibiting cyclooxygenase. It stops the formation of pain nerve impulses in inflammatory tissues and inhibits inflammatory reactions, including inhibiting the chemotaxis of leukocytes and the release of lysosomal enzymes. As for the antipyretic effect, it acts on the hypothalamic temperature regulation center, causing peripheral vasodilation and sweating, which increases heat dissipation. This central antipyretic effect may also be related to the inhibition of prostaglandin synthesis in the hypothalamus.

Under acidic conditions, it transforms into an active structure and combines with the SH group of the proton pump ((HK)-ATPase) to inhibit gastric acid secretion; it can inhibit the (HK)-ATPase activity in the microsomes of dog gastric mucosa; it has an inhibitory effect on the acid secretion of dog gastric mucosal parietal cells stimulated by histamine, acetylcholine and gastrin; it can significantly inhibit the acid secretion, nocturnal gastric acid secretion and 24-hour gastric acid secretion caused by gastrin or insulin stimulation in healthy adults; it has a significant and sustained inhibitory effect on the basal acid secretion and gastric acid secretion caused by various stimuli in rats; it promotes the healing of chronic gastric and duodenal ulcers in rats; it has a significant inhibitory effect on gastric ulcers, duodenal ulcers and reflux esophagitis caused by various reasons in rats.